https://www.selleckchem.com/pr....oducts/oprozomib-onx
Introduction Patients with phospholipase A2 receptor (PLA2R)-associated membranous nephropathy and stage 4 or 5 chronic kidney disease are at high risk of end-stage kidney disease. In recent years, rituximab (RTX) emerged as a safe and efficient treatment for patients with PLA2R-associated membranous nephropathy. Whether its use is also appropriate in patients with an estimated glomerular filtration rate less then 30 ml/min per 1.73 m2 has not been investigated. Methods We retrospectively reviewed characteristics and outcome
Like
Comment
Share
